March 29, 2017 / 9:50 PM / 5 months ago

BRIEF-Vanda and UCSF announce license agreement for CFTR activators and inhibitors

March 29 (Reuters) - Vanda Pharmaceuticals Inc -

* Vanda and UCSF announce license agreement for CFTR activators and inhibitors

* Under terms of deal, vanda will pay UCSF an initial license fee of $1 million and will be responsible for all development costs

* In 2017 intends to complete technology transfer activities from UCSF,initiate ind enabling studies for several CFTR indications

* To acquire exclusive worldwide license from UCSF to develop, commercialize portfolio of cftr activators, inhibitors Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below